Goldman Sachs initiates coverage on Workday with a Neutral rating, citing a crowded core market and a slower-than-expected AI strategy rollout. The firm identifies 2026 as a pivotal year for the HR and finance software giant to prove its technological evolution.
RBC Capital initiates coverage on Marvell Technology with an 'Outperform' rating, highlighting the chipmaker's strategic positioning in data center and custom AI silicon as key growth drivers.
Wells Fargo has upgraded Broadcom (AVGO) to Overweight and increased its price target to $430, pointing to the chipmaker's significant AI revenue trajectory and a robust software pipeline as key growth drivers through 2027.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
General Motors' stock climbed after the company raised its annual outlook, becoming a standout performer in Hotchkis & Wiley's value fund during a quarter marked by investor wariness over concentrated market gains.
CNBC's Jim Cramer offers a detailed take on NVIDIA's stock trajectory, highlighting analyst optimism around its data center partnerships while expressing skepticism over reported Chinese AI chip purchases.
CNBC's Jim Cramer highlights Micron Technology as a key beneficiary of the AI boom and ongoing memory chip shortages, with shares soaring nearly 400% in a year on robust data center demand.
Advanced Micro Devices (AMD) shares have soared over 115% in the past year, driven by its strategic positioning in the artificial intelligence sector. Recent analyst upgrades highlight optimism around its partnership with OpenAI and broader AI chip demand.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
A new industry analysis reveals the apparel and textiles sector is falling dangerously behind on its climate commitments, with progress too slow to meet critical international targets.
New research reveals a stark preparedness gap among UK manufacturers and wholesalers for the impending EU Digital Product Passport (DPP), with nearly half unaware of the regulation that could bar non-compliant goods from the single market.
Precious metals continue their historic surge, outpacing the S&P 500 for a third consecutive year. We examine the powerful drivers behind the rally, from industrial demand to monetary policy, and explore how investors can gain exposure through ETFs while navigating the risks.
Preliminary Eurostat data reveals Spain and Portugal grew at more than double the eurozone average in Q4 2025, driven by resilient domestic demand and strategic advantages, while the broader bloc's recovery remains uneven.
German automotive giant Bosch reports a sharp 45% drop in operating profit for 2025, driven by heavy restructuring charges, intense global competition, and delayed returns on future-tech investments.
Campbell Soup Company will close its Hyannis, Massachusetts snack facility by April, consolidating production of Cape Cod and Kettle Brand chips at other US plants amid declining sales in its snacks division.
Federal prosecutors unseal indictments against the CEO and senior vice president of First Brands Group, alleging a complex financial fraud that contributed to the company's recent bankruptcy.
The Eurozone economy grew 0.3% in Q4 2025, matching the previous quarter's pace and easing earlier recession fears. However, analysts warn that the euro's sharp 14.4% gain against the dollar over the past year threatens to undermine the competitiveness of European exports.
The new campus in McBee, SC, aims to bolster North American supply chains for critical minerals, starting with a 2,000-ton annual processing capacity for magnet scrap.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
